COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 1 for:    OP-1250
Previous Study | Return to List | Next Study

A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04505826
Recruitment Status : Recruiting
First Posted : August 10, 2020
Last Update Posted : August 20, 2020
Information provided by (Responsible Party):
Olema Pharmaceuticals, Inc.

Brief Summary:
This clinical trial is a Phase 1-2, open-label, multi-center, dose-escalation and expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of daily oral administration of OP-1250.

Condition or disease Intervention/treatment Phase
Hormone Receptor Positive Breast Carcinoma HER2-negative Breast Cancer Drug: OP-1250 Phase 1 Phase 2

Detailed Description:
OP-1250 is a small molecule Complete Estrogen Receptor ANtagonist (CERAN). OP-1250 potently competes with the endogenous activating estrogenic ligand 17-beta estradiol for binding in the ligand binding pocket. OP-1250 blocks estrogen-driven transcriptional activity, inhibits estrogen-driven breast cancer cell growth, and induces degradation of the estrogen receptor.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 94 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Open-label, First-in-Human, Multicenter, Dose Escalation and Dose Expansion Study of OP-1250 Monotherapy in Adult Subjects With Advanced and/or Metastatic Hormone Receptor (HR)-Positive, HER2-negative Breast Cancer
Actual Study Start Date : August 13, 2020
Estimated Primary Completion Date : October 2023
Estimated Study Completion Date : December 2023

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: OP-1250 Dose Escalation
This portion of the study will evaluate the safety and pharmacology of a range of OP-1250 doses administered daily in subjects with advanced and/or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer and to determine the RP2D
Drug: OP-1250
Complete Estrogen Receptor ANtagonist (CERAN)

Experimental: OP-1250 Expansion
This portion of the study further explores the clinical activity, safety and pharmacology of OP-1250 monotherapy at the RP2D and to estimate preliminary data of anti-tumor efficacy
Drug: OP-1250
Complete Estrogen Receptor ANtagonist (CERAN)

Primary Outcome Measures :
  1. Determine MTD and/or RP2D of OP-1250 when used as a single agent [ Time Frame: Up to one year ]
    Number of patients with DLT as defined in the protocol

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Must not have received prior oral endocrine therapy > 2 weeks prior to first dose
  • Must not have received prior fulvestrant, chemotherapy, antibody therapy, or investigational therapy ≤ 4 weeks prior to the first dose
  • Adequate hepatic function
  • Adequate renal function
  • Normal coagulation panel
  • Willingness to use effective contraception

Exclusion Criteria:

  • Gastrointestinal disease
  • Significant renal disease
  • Significant cardiovascular disease
  • Significant ECG abnormalities
  • Ongoing systemic bacterial, fungal, or viral infection (requiring antimicrobial therapy)
  • Pregnancy or breastfeeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04505826

Layout table for location contacts
Contact: There may be multiple sites in this clinical trial. (415) 651-7206

Layout table for location information
United States, Florida
Advent Health Recruiting
Orlando, Florida, United States, 32804
Contact: Ingrid Acker    407-303-2090   
Florida Cancer Center Recruiting
Sarasota, Florida, United States, 34232
Contact: Heather Williams    941-377-9993   
United States, Tennessee
Sarah Cannon Research Institute Recruiting
Nashville, Tennessee, United States, 37203
Contact: Maddie Kolbe    615-524-4456   
Sponsors and Collaborators
Olema Pharmaceuticals, Inc.
Layout table for investigator information
Study Director: Jo Anne Zujewski, MD Olema Pharmaceuticals, Inc.
Study Director: Trinh Le Olema Pharmaceuticals, Inc.
Layout table for additonal information
Responsible Party: Olema Pharmaceuticals, Inc. Identifier: NCT04505826    
Other Study ID Numbers: OP-1250-001
First Posted: August 10, 2020    Key Record Dates
Last Update Posted: August 20, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases